'We have had a number of breakthroughs and we will continue to work on them'
’s Sunday with Laura Kuenssberg. They co-founded BioNTech in Mainz, Germany in 2008 and worked to pioneer cancer immunotherapies which can be tailored to individual patients.
While conventional vaccines are produced using weakened forms of a virus, mRNAs use only a virus’s genetic code. Asked when cancer vaccines might be accessed by many patients around the world, Prof Sahin said it could happen “before 2030”.Prof Tureci told Kuenssberg: “What we have developed over decades for cancer vaccine development has been the tailwind for developing the Covid-19 vaccine, and now the Covid-19 vaccine and our experience in developing it gives back to our cancer work.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: